FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Baker

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Andrew H Baker; Christian Delles
Is microRNA-376c a biomarker or mediator of preeclampsia?
Angela C Bradshaw; Andrew H Baker
Gene therapy for cardiovascular disease: perspectives and potential.
Angela C Bradshaw; Lynda Coughlan; Ashley M Miller; Stuart A Nicklin; Nico van Rooijen; Raul Alba; Andrew H Baker
Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Baker (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrew H Baker; Christian Delles
Is microRNA-376c a biomarker or mediator of preeclampsia?
Hypertension 2013;61(4):767-9.
2013: Angela C Bradshaw; Andrew H Baker
Gene therapy for cardiovascular disease: perspectives and potential.
Vascular pharmacology 2013;58(3):174-81.
2012: Angela C Bradshaw; Lynda Coughlan; Ashley M Miller; Stuart A Nicklin; Nico van Rooijen; Raul Alba; Andrew H Baker
Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
Journal of controlled release : official journal of the Controlled Release Society 2012;164(3):394-402.
2012: Helen E Chick; Christian Delles; Raffaele Fronza; Nicole M Kane; Robert A McDonald; Ali Nowrouzi; Manfred Schmidt; William C Sessa; Adrian J Thrasher; Raul Alba; Andrew H Baker
Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk.
Human gene therapy 2012;23(12):1247-57.
2012: Lynda Coughlan; Jerome Custers; Jaap Goudsmit; Stuart A Nicklin; Alan L Parker; Hollie Robinson; Nico Van Roijen; Katie White; Dan H Barouch; Angela C Bradshaw; Andrew H Baker
Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(12):2268-81.
2012: Hollie C Robinson; Andrew H Baker
How do microRNAs affect vascular smooth muscle cell biology?
Current opinion in lipidology 2012;23(5):405-11.
2012: Keith E Robertson; Robert A McDonald; Stuart A Nicklin; Keith G Oldroyd; Andrew H Baker
Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role?
Pharmacology & therapeutics 2012;136(1):23-34.
2012: Lynda Coughlan; Marta Giménez-Alejandre; Alena Gros; Ramon Alemany; Andrew H Baker; Manel Cascalló; Gareth J Thomas; Sabari Vallath; N Van Rooijen; Ian R Hart
Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Human gene therapy 2012;23(9):960-79.
2012: Ian Morecroft; Margaret Nilsen; Paul N Reynolds; Katie White; Raul Alba; Andrew H Baker; Paola Caruso; Sergei M Danilov; Lynn Loughlin; Margaret R MacLean
Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(8):1516-28.
2012: Paola Caruso; Yvonne Dempsie; Lu Long; Ruifang Lu; Margaret R MacLean; Kirsty M Mair; John D McClure; Robert A McDonald; Nicholas W Morrell; Eric N Olson; Mark Southwood; Hannah C Stevens; Paul Upton; Eva van Rooij; Kevin White; Mei Xin; Andrew H Baker
A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.
Circulation research 2012;111(3):290-300.
2012: Katie White; Nicole M Kane; Graeme Milligan; Andrew H Baker
The role of miRNA in stem cell pluripotency and commitment to the vascular endothelial lineage.
Microcirculation (New York, N.Y. : 1994) 2012;19(3):196-207.
2012: Nicole M Kane; Ruifang Lu; Ruth M Mackenzie; Angela McCahill; John McClure; Marco Meloni; Graeme Milligan; joanne mountford; Christopher Breen; Christian Delles; Betty Descamps; Costanza Emanueli; Lynsey Howard; Andrew H Baker
Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells.
Stem cells (Dayton, Ohio) 2012;30(4):643-54.
2012: Robert A McDonald; Nicholas W Morrell; Akiko Hata; Margaret R MacLean; Andrew H Baker
MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling.
Cardiovascular research 2012;93(4):594-604.
2012: Margaret R Duffy; Alan L Parker; Angela C Bradshaw; Andrew H Baker
Manipulation of adenovirus interactions with host factors for gene therapy applications.
Nanomedicine (London, England) 2012;7(2):271-88.
2012: Raul Alba; Andrew H Baker; Stuart A Nicklin
Vector systems for prenatal gene therapy: principles of adenovirus design and production.
Methods in molecular biology (Clifton, N.J.) 2012;891():55-84.
2011: Lynsey Howard; Nicole M Kane; Graeme Milligan; Andrew H Baker
MicroRNAs regulating cell pluripotency and vascular differentiation.
Vascular pharmacology 2011;55(4):69-78.
2011: Margaret R Duffy; John H McVey; Alan L Parker; Angela C Bradshaw; Andrew H Baker
A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes.
Journal of virology 2011;85(20):10914-9.
2011: Andrew H Baker
MicroRNA 21 "shapes" vascular smooth muscle behavior through regulating tropomyosin 1.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(9):1941-2.
2011: Kevin White; Lynn Loughlin; Zakia Maqbool; Margaret Nilsen; John McClure; Yvonne Dempsie; Andrew H Baker; Margaret R MacLean
Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH.
Physiological genomics 2011;43(8):417-37.
2011: Janne P Kallio; Sally Hopkins-Donaldson; Andrew H Baker; Veli-Matti Kähäri
TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway.
International journal of cancer. Journal international du cancer 2011;128(4):991-6.
2011: Andrea Caporali; Marco Meloni; Christine Völlenkle; Desiree Bonci; Graciela B Sala-Newby; Roberta Addis; Gaia Spinetti; Sergio Losa; Rachel Masson; Andrew H Baker; Reuven Agami; Carlos le Sage; Gianluigi Condorelli; Paolo Madeddu; Fabio Martelli; Costanza Emanueli
Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia.
Circulation 2011;123(3):282-91.
2011: Nicole Kane; Qingzhong Xiao; Andrew H Baker; Zhenling Luo; Qingbo Xu; Costanza Emanueli
Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re(generation).
Pharmacology & therapeutics 2011;129(1):29-49.
2010: Peter Burton; David R Adams; Achamma Abraham; Robert W Allcock; Zhong Jiang; Angela McCahill; Jane Gilmour; John McAbney; Alexandra Kaupisch; Nicole Kane; George S Baillie; Andrew H Baker; Graeme Milligan; Miles D Houslay; joanne mountford
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells.
The Biochemical journal 2010;432(3):575-84.
2010: Nicole Kane; Ali Nowrouzi; Sayandip Mukherjee; Michael P Blundell; Jenny A Greig; Wai Kwong Lee; Miles D Houslay; Graeme Milligan; joanne mountford; Christof von Kalle; Manfred Schmidt; Adrian J Thrasher; Andrew H Baker
Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(12):2139-45.
2010: Jenny A Greig; Rachel Shirley; Delyth Graham; Laura Denby; Anna F Dominiczak; Lorraine M Work; Andrew H Baker
Vascular-targeting antioxidant therapy in a model of hypertension and stroke.
Journal of cardiovascular pharmacology 2010;56(6):642-50.
2010: Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; André Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.
Blood 2010;116(15):2656-64.
2010: Lynda Coughlan; Iain A McNeish; Stuart A Nicklin; Alan L Parker; Raul Alba; Angela C Bradshaw; Andrew H Baker
Tropism-modification strategies for targeted gene delivery using adenoviral vectors.
Viruses 2010;2(10):2290-355.
2010: Peter Burton; David R Adams; Achamma Abraham; Robert W Allcock; Zhong Jiang; Angela McCahill; Jane Gilmour; John McAbney; Nicole Kane; George S Baillie; Fergus R McKenzie; Andrew H Baker; Miles D Houslay; joanne mountford; Graeme Milligan
Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells.
Biochemical Society transactions 2010;38(4):1058-61.
2010: Nicole Kane; Marco Meloni; Helen L Spencer; Margaret A Craig; Raimund Strehl; Graeme Milligan; Miles D Houslay; joanne mountford; Costanza Emanueli; Andrew H Baker
Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(7):1389-97.
2010: Paola Caruso; Margaret R MacLean; Raya Khanin; John McClure; Elaine Soon; Mark Southgate; Robert A MacDonald; Jenny A Greig; Keith E Robertson; Rachel Masson; Laura Denby; Yvonne Dempsie; Lu Long; Nicholas W Morrell; Andrew H Baker
Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(4):716-23.
2010: Angela C Bradshaw; Alan L Parker; Margaret R Duffy; Lynda Coughlan; Nico van Rooijen; Veli-Matti Kähäri; Stuart A Nicklin; Andrew H Baker
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.
PLoS pathogens 2010;6(10):e1001142.
2009: Jenny A Greig; Suzanne Mk Buckley; Simon Waddington; Alan L Parker; David Bhella; Rebecca Pink; Ahad A Rahim; Takashi Morita; Stuart A Nicklin; John H McVey; Andrew H Baker
Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(10):1683-91.
2009: Raul Alba; Angela C Bradshaw; Alan L Parker; David Bhella; Simon Waddington; Stuart A Nicklin; Nico van Rooijen; Jerome Custers; Jaap Goudsmit; Dan H Barouch; John H McVey; Andrew H Baker
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.
Blood 2009;114(5):965-71.
2009: Campbell G Nicol; Laura Denby; Oscar Lopez-Franco; Rachel Masson; Crawford A Halliday; Stuart A Nicklin; Angelika Kritz; Lorraine M Work; Andrew H Baker
Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature.
FEBS letters 2009;583(12):2100-7.
2009: Rachel Masson; Stuart A Nicklin; Margaret Anne Craig; Martin McBride; Kirsten Gilday; Paul Gregorevic; James M Allen; Jeffrey S Chamberlain; Godfrey Smith; Delyth Graham; Anna F Dominiczak; Claudio Napoli; Andrew H Baker
Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2.
Hypertension 2009;53(4):694-700.
2009: Alan L Parker; Simon Waddington; Suzanne Buckley; Jerome Custers; Menzo J E Havenga; Nico van Rooijen; Jaap Goudsmit; John H McVey; Stuart A Nicklin; Andrew H Baker
Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.
Journal of virology 2009;83(1):479-83.
2008: Stuart A Nicklin; Andrew H Baker
Efficient vascular endothelial gene transfer following intravenous adenovirus delivery.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(12):1904-5.
2008: Angelika B Kritz; Jun Yu; Paulette L Wright; Song Wan; Sarah George; Crawford Halliday; Ning Kang; William C Sessa; Andrew H Baker
In vivo modulation of Nogo-B attenuates neointima formation.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(11):1798-804.
2008: Suzanne Buckley; Steven J Howe; Ahad A Rahim; Hildegard Buning; Jenny McIntosh; Suet-Ping Wong; Andrew H Baker; Amit Nathwani; Adrian J Thrasher; Charles Coutelle; Tristan R McKay; Simon Waddington
Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration.
Human gene therapy 2008;19(10):1050-6.
2008: Alan L Parker; Stuart A Nicklin; Andrew H Baker
Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications.
Current opinion in molecular therapeutics 2008;10(5):439-48.
2008: Andrew V Benest; Oliver A Stone; William H Miller; Colin P Glover; James B Uney; Andrew H Baker; Steven J Harper; David O Bates
Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(8):1462-8.
2008: K White; Hildegard Büning; A Kritz; H Janicki; J McVey; L Perabo; G Murphy; Margarete Odenthal; Lorraine M Work; Michael Hallek; Stuart A Nicklin; Andrew H Baker
Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.
Gene therapy 2008;15(6):443-51.
2008: Ashley M Miller; Damo Xu; Darren L Asquith; Laura Denby; Yubin Li; Naveed Sattar; Andrew H Baker; Iain B McInnes; Foo Y Liew
IL-33 reduces the development of atherosclerosis.
The Journal of experimental medicine 2008;205(2):339-46.
2008: Simon Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Adenovirus serotype 5 hexon mediates liver gene transfer.
Cell 2008;132(3):397-409.
2008: Tracey Graham; Jenny McIntosh; Lorraine M Work; Amit Nathwani; Andrew H Baker
Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats.
Genetic vaccines and therapy 2008;6():9.
2007: Andrew H Baker
Adenovirus toxicity and tropism in vivo: not as simple as A,B,C (or D,E,F).
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(12):2061-2.
2007: Simon Waddington; Alan L Parker; Menzo J E Havenga; Stuart A Nicklin; Suzanne Buckley; John H McVey; Andrew H Baker
Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.
Journal of virology 2007;81(17):9568-71.
2007: Laura Denby; Lorraine M Work; Dan J Von Seggern; Eugene Wu; John H McVey; Stuart A Nicklin; Andrew H Baker
Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(9):1647-54.
2007: Andrew H Baker; John H McVey; Simon Waddington; Nelson C Di Paolo; Dmitry M Shayakhmetov
The influence of blood on in vivo adenovirus bio-distribution and transduction.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(8):1410-6.
2007: Kathryn White; Stuart A Nicklin; Andrew H Baker
Novel vectors for in vivo gene delivery to vascular tissue.
Expert opinion on biological therapy 2007;7(6):809-21.
2007: Alan L Parker; John H McVey; Jessica H Doctor; Oscar Lopez-Franco; Simon Waddington; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.
Journal of virology 2007;81(7):3627-31.
2007: Angelika B Kritz; Campbell G Nicol; Kate L Dishart; Ruth Nelson; Susan Holbeck; Dan J Von Seggern; Lorraine M Work; John H McVey; Stuart A Nicklin; Andrew H Baker
Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(4):741-9.
2007: Barry W McColl; Ailsa L McGregor; Andrew Wong; Julian Harris; Andrea Amalfitano; Sandra Magnoni; Andrew H Baker; George Dickson; Karen Horsburgh
APOE epsilon3 gene transfer attenuates brain damage after experimental stroke.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2007;27(3):477-87.
2007: Andrew H Baker; Vincenzo Sica; Lorraine M Work; Sharon Williams-Ignarro; Filomena de Nigris; Lilach O Lerman; Amelia Casamassimi; Alessandro Lanza; Concetta Schiano; Monica Rienzo; Louis J Ignarro; Claudio Napoli
Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(9):3597-602.
2007: Mervi J Toriseva; Risto Ala-Aho; Jarkko Karvinen; Andrew H Baker; Varpu S Marjomäki; Jyrki Heino; Veli-Matti Kähäri
Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts.
The Journal of investigative dermatology 2007;127(1):49-59.
2006: Alan L Parker; Simon Waddington; Campbell G Nicol; Dmitry M Shayakhmetov; Suzanne Buckley; Laura Denby; Geoffrey Kemball-Cook; Shaoheng Ni; André Lieber; John H McVey; Stuart A Nicklin; Andrew H Baker
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.
Blood 2006;108(8):2554-61.
2006: Sarah George; Keith M Channon; Andrew H Baker
Gene therapy and coronary artery bypass grafting: current perspectives.
Current opinion in molecular therapeutics 2006;8(4):288-94.
2006: Luca Perabo; Daniela Goldnau; Kathryn White; Jan Endell; Jorge Boucas; Sibille Humme; Lorraine M Work; Hanna Janicki; Michael Hallek; Andrew H Baker; Hildegard Büning
Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.
Journal of virology 2006;80(14):7265-9.
2006: Jason L Johnson; Andrew H Baker; Kazuhiro Oka; Lawrence Chan; Andrew C Newby; Christopher L Jackson; Sarah George
Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis.
Circulation 2006;113(20):2435-44.
2006: Lorraine M Work; Hildegard Büning; Ela Hunt; Stuart A Nicklin; Laura Denby; Nicola Britton; Kristin Leike; Margarete Odenthal; Uta Drebber; Michael Hallek; Andrew H Baker
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(4):683-93.
2006: Andrew H Baker; Anthony P C Yim; Song Wan
Opportunities for gene therapy in preventing vein graft failure after coronary artery bypass surgery.
Diabetes, obesity & metabolism 2006;8(2):119-24.
2005: Laura Denby; Stuart A Nicklin; Andrew H Baker
Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.
Gene therapy 2005;12(20):1534-8.
2005: Stuart A Nicklin; Eugene Wu; Glen R Nemerow; Andrew H Baker
The influence of adenovirus fiber structure and function on vector development for gene therapy.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;12(3):384-93.
2005: William H Miller; M Julia Brosnan; Delyth Graham; Campbell G Nicol; Ian Morecroft; Keith M Channon; Sergei M Danilov; Paul N Reynolds; Andrew H Baker; Anna F Dominiczak
Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;12(2):321-7.
2005: Stephen J White; Rachel E Simmonds; David A Lane; Andrew H Baker
Efficient isolation of peptide ligands for the endothelial cell protein C receptor (EPCR) using candidate receptor phage display biopanning.
Peptides 2005;26(7):1264-9.
2005: Lorraine M Work; Campbell G Nicol; Laura Denby; Andrew H Baker
In vivo biopanning: A methodological approach to identifying novel targeting ligands for delivery of biological agents to the vasculature.
Methods in molecular medicine 2005;108():395-413.
2005: Alan L Parker; Kerry D Fisher; David Oupický; Martin L Read; Stuart A Nicklin; Andrew H Baker; Leonard W Seymour
Enhanced gene transfer activity of peptide-targeted gene-delivery vectors.
Journal of drug targeting 2005;13(1):39-51.
2005: Andrew H Baker; Angelika Kritz; Lorraine M Work; Stuart A Nicklin
Cell-selective viral gene delivery vectors for the vasculature.
Experimental physiology 2005;90(1):27-31.
2004: Laura Denby; Lorraine M Work; Delyth Graham; Catherine Hsu; Dan J Von Seggern; Stuart A Nicklin; Andrew H Baker
Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo.
Human gene therapy 2004;15(11):1054-64.
2004: Campbell G Nicol; Delyth Graham; William H Miller; Stephen J White; Theodore A G Smith; Stuart A Nicklin; Susan C Stevenson; Andrew H Baker
Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;10(2):344-54.
2004: Lorraine M Work; N Ritchie; Stuart A Nicklin; Paul N Reynolds; Andrew H Baker
Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control.
Gene therapy 2004;11(16):1296-300.
2004: E D Papadakis; Stuart A Nicklin; Andrew H Baker; S J White
Promoters and control elements: designing expression cassettes for gene therapy.
Current gene therapy 2004;4(1):89-113.
2004: Stuart A Nicklin; Steve J White; Campbell G Nicol; Dan J Von Seggern; Andrew H Baker
In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors.
The journal of gene medicine 2004;6(3):300-8.
2004: Stephen J White; Stuart A Nicklin; Hildegard Büning; M Julia Brosnan; Kristin Leike; Emmanuel D Papadakis; Michael Hallek; Andrew H Baker
Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.
Circulation 2004;109(4):513-9.
2004: Andrew H Baker
Designing gene delivery vectors for cardiovascular gene therapy.
Progress in biophysics and molecular biology 2004;84(2-3):279-99.
2004: Lorraine M Work; Stuart A Nicklin; Nick J R Brain; Kate L Dishart; Dan J Von Seggern; Michael Hallek; Hildegard Büning; Andrew H Baker
Development of efficient viral vectors selective for vascular smooth muscle cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(2):198-208.
2003: Stuart A Nicklin; Kate L Dishart; Hildegard Buening; Paul N Reynolds; Michael Hallek; Glen R Nemerow; Dan J Von Seggern; Andrew H Baker
Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors.
Cancer letters 2003;201(2):165-73.
2003: Hildegard Büning; Stuart A Nicklin; Luca Perabo; Michael Hallek; Andrew H Baker
AAV-based gene transfer.
Current opinion in molecular therapeutics 2003;5(4):367-75.
2003: Filomena de Nigris; Amir Lerman; Louis J Ignarro; Sharon Williams-Ignarro; Vincenzo Sica; Andrew H Baker; Lilach O Lerman; Yong J Geng; Claudio Napoli
Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis.
Trends in molecular medicine 2003;9(8):351-9.
2003: Kate L Dishart; Laura Denby; Sarah George; Stuart A Nicklin; Satya Yendluri; Melanie J Tuerk; Michael P Kelley; Brian A Donahue; Andrew C Newby; Thomas C Harding; Andrew H Baker
Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy.
Journal of molecular and cellular cardiology 2003;35(7):739-48.
2003: Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Targeting gene therapy vectors to the vascular endothelium.
Current atherosclerosis reports 2003;5(3):163-70.
2003: Matti Ahonen; Minna Poukkula; Andrew H Baker; Masahide Kashiwagi; Hideaki Nagase; John E Eriksson; Veli-Matti Kähäri
Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors.
Oncogene 2003;22(14):2121-34.
2003: Andrew H Baker
Targeting AAV vectors.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(4):433-4.
2003: Stuart A Nicklin; Andrew H Baker
Development of targeted viral vectors for cardiovascular gene therapy.
Genetic engineering 2003;25():15-49.
2003: Henry K K Tan; Darren J Heywood; G Scott Ralph; Alison S Bienemann; Andrew H Baker; James B Uney
Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons.
Molecular and cellular neurosciences 2003;22(1):98-106.
2002: Andrew H Baker
Development and use of gene transfer for treatment of cardiovascular disease.
Journal of cardiac surgery 2002;17(6):543-8.
2002: Mohammed A Majid; Valerie A Smith; David L Easty; Andrew H Baker; Andrew C Newby
Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells.
FEBS letters 2002;529(2-3):281-5.
2002: Sarah George; Andrew H Baker
Gene transfer to the vasculature: historical perspective and implication for future research objectives.
Molecular biotechnology 2002;22(2):153-64.
2002: Andrew H Baker; Dylan R Edwards; Gillian Murphy
Metalloproteinase inhibitors: biological actions and therapeutic opportunities.
Journal of cell science 2002;115(Pt 19):3719-27.
2002: Andrew H Baker
Gene therapy for bypass graft failure and restenosis.
Pathophysiology of haemostasis and thrombosis 2002;32(5-6):389-91.
2002: Stuart A Nicklin; Andrew H Baker
Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy.
Current gene therapy 2002;2(3):273-93.
2002: Matti Ahonen; Risto Ala-Aho; Andrew H Baker; Sarah George; Reidar Grénman; Ulpu Saarialho-Kere; Veli-Matti Kähäri
Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3.
Molecular therapy : the journal of the American Society of Gene Therapy 2002;5(6):705-15.
2002: Mark Bond; Gillian Murphy; Martin R Bennett; Andrew C Newby; Andrew H Baker
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.
The Journal of biological chemistry 2002;277(16):13787-95.
2002: Risto Ala-Aho; Nina Johansson; Andrew H Baker; Veli-Matti Kähäri
Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells.
International journal of cancer. Journal international du cancer 2002;97(3):283-9.
2002: Lorraine M Work; Stuart A Nicklin; Steve J White; Andrew H Baker
Use of phage display to identify novel peptides for targeted gene therapy.
Methods in enzymology 2002;346():157-76.
2002: Jerome Fennell; M Julia Brosnan; A J Frater; Carlene A Hamilton; MY Alexander; Stuart A Nicklin; D D Heistad; Andrew H Baker; Anna F Dominiczak
Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension.
Gene therapy 2002;9(2):110-7.
2002: Mohammed A Majid; Valerie A Smith; David L Easty; Andrew H Baker; Andrew C Newby
Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells.
The British journal of ophthalmology 2002;86(1):97-101.
2001: Stuart A Nicklin; Dan J Von Seggern; Lorraine M Work; D C Pek; Anna F Dominiczak; Glen R Nemerow; Andrew H Baker
Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(6):534-42.
2001: Stuart A Nicklin; Hildegard Buening; Kate L Dishart; Mahesh De Alwis; A Girod; Ulrich T Hacker; Adrian J Thrasher; Robin R Ali; Michael Hallek; Andrew H Baker
Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(3):174-81.
2001: Stuart A Nicklin; Paul N Reynolds; M Julia Brosnan; S J White; D T Curiel; Anna F Dominiczak; Andrew H Baker
Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium.
Hypertension 2001;38(1):65-70.
2001: Mark Bond; A J Chase; Andrew H Baker; Andrew C Newby
Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells.
Cardiovascular research 2001;50(3):556-65.
2001: Sarah George; Gianni Angelini; M C Capogrossi; Andrew H Baker
Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis.
Gene therapy 2001;8(9):668-76.
2001: S J White; Stuart A Nicklin; T Sawamura; Andrew H Baker
Identification of peptides that target the endothelial cell-specific LOX-1 receptor.
Hypertension 2001;37(2 Pt 2):449-55.
2001: C T Lloyd; Sarah George; G D Angelini; A C Newby; Andrew H Baker
A pig model of vein graft disease applications for potential gene therapies.
Methods in molecular medicine 2001;52():233-43.
2001: Sarah George; Andrew H Baker
Gene transfer to the vasculature historical perspective and implications for future research objectives.
Methods in molecular medicine 2001;52():219-31.
2000: Mark Bond; Gillian Murphy; Martin R Bennett; Augustin Amour; Vera Knauper; Andrew C Newby; Andrew H Baker
Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity.
The Journal of biological chemistry 2000;275(52):41358-63.
2000: Stuart A Nicklin; S J White; SJ Watkins; Robert E Hawkins; Andrew H Baker
Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display.
Circulation 2000;102(2):231-7.
2000: Sarah George; Clinton T Lloyd; Gianni Angelini; Andrew C Newby; Andrew H Baker
Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3.
Circulation 2000;101(3):296-304.
2000: Andrew H Baker; Matti Ahonen; Veli-Matti Kähäri
Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy.
Advances in experimental medicine and biology 2000;465():469-83.
1999: Mark Bond; Andrew H Baker; Andrew C Newby
Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts.
Biochemical and biophysical research communications 1999;264(2):561-7.
1999: Andrew H Baker; Sarah George; AB Zaltsman; Gillian Murphy; Andrew C Newby
Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.
British journal of cancer 1999;79(9-10):1347-55.
1999: A Kranzhöfer; Andrew H Baker; Sarah George; Andrew C Newby
Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(2):255-65.
1999: Sarah George; Andrew H Baker
Delivery of recombinant adenoviruses to human saphenous vein.
Methods in molecular medicine 1999;30():357-64.
1999: Stuart A Nicklin; Andrew H Baker
Simple methods for preparing recombinant adenoviruses for high-efficiency transduction of vascular cells.
Methods in molecular medicine 1999;30():271-83.
1998: Sarah George; Andrew H Baker; Gianni Angelini; Andrew C Newby
Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins.
Gene therapy 1998;5(11):1552-60.
1998: Mark Bond; R P Fabunmi; Andrew H Baker; Andrew C Newby
Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B.
FEBS letters 1998;435(1):29-34.
1998: Matti Ahonen; Andrew H Baker; Veli-Matti Kähäri
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells.
Cancer research 1998;58(11):2310-5.
1998: Sarah George; Jason Lee Johnson; Gianni Angelini; Andrew C Newby; Andrew H Baker
Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein.
Human gene therapy 1998;9(6):867-77.
1998: Andrew H Baker; AB Zaltsman; Sarah George; Andrew C Newby
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.
The Journal of clinical investigation 1998;101(6):1478-87.
1998: Matti Ahonen; Andrew H Baker; Veli-Matti Kähäri
High level expression of tissue inhibitors of metalloproteinases-1,-2 and -3 in melanoma cells achieved by adenovirus mediated gene transfer.
Advances in experimental medicine and biology 1998;451():69-72.
1997: Andrew H Baker; D Mehta; Sarah George; Gianni Angelini
Prevention of vein graft failure: potential applications for gene therapy.
Cardiovascular research 1997;35(3):442-50.